Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors - Test2 - elhamkhani - TriplyDB

Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors

Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors

http://www.wikidata.org/entity/Q34104493

about

Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets EGFR Signaling in Liver Diseases An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma Current diagnostic and management options in perihilar cholangiocarcinoma Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies Cancer review: Cholangiocarcinoma The significance of genetics for cholangiocarcinoma development Cholangiocarcinoma Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies Genetic profiling of intrahepatic cholangiocarcinoma Progression of targeted therapy in advanced cholangiocarcinoma Evaluation of database-derived pathway development for enabling biomarker discovery for hepatotoxicity Molecular profiling of biliary tract cancer: a target rich disease Cholangiocarcinoma: Current Knowledge and New Developments Classification, diagnosis, and management of cholangiocarcinoma Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures Targeting Angiogenesis in Biliary Tract Cancers: An Open Option Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets.miR-34a-dependent overexpression of Per1 decreases cholangiocarcinoma growth.DMBT1 expression in biliary carcinogenesis with correlation of clinicopathological data.Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles.Intrahepatic cholangiocarcinoma Management of unresectable intrahepatic cholangiocarcinoma: how do we decide among the various liver-directed treatments?Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups.Molecular pathogenesis of cholangiocarcinoma.p53-dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine.Systemic Therapy of Cholangiocarcinoma.Pathogenesis, diagnosis, and management of cholangiocarcinoma EGFR, FLT1 and heparanase as markers identifying patients at risk of short survival in cholangiocarcinoma Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma.Cholangiocarcinoma: molecular pathways and therapeutic opportunities New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.Tumoral heterogeneity of hepatic cholangiocarcinomas revealed by MALDI imaging mass spectrometry.Patterns of chromosomal copy-number alterations in intrahepatic cholangiocarcinoma Prognostic value of neutrophil distribution in cholangiocarcinoma.Molecular diagnosis of intrahepatic cholangiocarcinoma.Liver cancer: Approaching a personalized care.

P2860

Q24610836-7881BF9A-4A69-4DE4-8419-80D23BF30349 Q26751224-4F49DD81-E75C-4E0B-9BA6-EAD5FC97B159 Q26771265-44DA5FC6-602B-41A2-BDF0-620997491443 Q26784091-572C823A-302D-43F1-9782-BFE97A2C1EDA Q26822808-13D954CB-9683-40EA-98EE-86F113BAA260 Q26830194-F623BCCF-7363-47CB-92BF-263A8CCB875E Q26852049-39CAC8C8-8D34-4AAF-A3D6-B97A797D2109 Q26865200-43401794-4834-4595-9FB1-164D17B57436 Q26865749-761FE401-6202-461E-832E-0EC54F0D7764 Q27001694-EDDB300B-D5EF-456E-A06B-BAAF1B191C10 Q27002547-51BA0EC7-6D63-406D-9571-DBAE5BE7E96B Q27005787-F037ECC7-DF14-4900-8738-D2F7C0A365E5 Q27016150-EB4BEEFA-02B5-4181-B89C-3720E0EAB33E Q27027301-DB8E0DC0-42B5-4DF9-8411-3CEF07F6FF29 Q28072275-776DEA8C-54DA-45CF-943C-2471A90F8079 Q28076098-42001B94-9526-4ED5-A5D0-AD8AEB6C54EE Q28275153-19E8B147-6E78-4454-B13A-27127265D9F5 Q28550991-5B4ED9B3-DCE6-437A-836A-7CD087B5F064 Q30398807-7B44AD1B-685B-4842-A261-8C781E94208D Q30405398-006CB21A-E81A-4C1D-BE3B-38F3E9238389 Q30760000-AE4218F6-F479-45A3-B645-52DE703FBDA4 Q31157475-FAA78109-4A2E-4C9A-B810-8D05A8E3010E Q32173000-6097B659-F46E-4AD8-A06D-441A8735719B Q33555135-705D6ECC-7B72-409F-ABF6-44C39E7A8A87 Q33621522-4C11DA92-3981-4E42-815B-0446FF2ACD91 Q33757122-8A25D52C-9B30-4ED9-8678-44E44F9506D6 Q34065560-D9487BCC-8981-4D2D-B781-7C360A67E233 Q34457367-1B6B472A-E264-46BA-9EBB-4ED157DE3824 Q34550326-DA53D842-12A9-470D-AE2A-4621E168F97B Q34551877-76EB3D9E-2E30-4CB8-9E40-B0422931811C Q34656747-CE74DE92-4711-4710-A551-1951001ABFB1 Q34738001-814B7945-0393-408F-9423-43BEB57CD51F Q34775377-6367EF95-6B62-4D38-995C-15F2F0B52E20 Q34959174-5036B3F3-96A0-4F7C-8608-8F3F4B69F474 Q35100996-E1E79180-04DD-4914-81F0-F5811E3DF7F8 Q35134122-B99A6520-9CE9-4623-A020-30FEB1D527CF Q35215602-1AA63D3E-0FCF-4D4C-A9A6-2BBBB5216BDE Q35534078-1DB5CBE6-1AD8-48D4-A1B7-BF35AB00B960 Q35592221-81531598-C0CB-4167-B0A1-CA14971A8C27 Q35903794-FF3A364E-E783-4CB5-90B4-A9974A14D1BF

P2860

Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors

http://www.wikidata.org/entity/Q34104493

description

2011 nî lūn-bûn

@nan

2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Genomic and genetic characteri ...... for tyrosine kinase inhibitors

@ast

Genomic and genetic characteri ...... for tyrosine kinase inhibitors

@en

Genomic and genetic characteri ...... for tyrosine kinase inhibitors

@nl

type

label

Genomic and genetic characteri ...... for tyrosine kinase inhibitors

@ast

Genomic and genetic characteri ...... for tyrosine kinase inhibitors

@en

Genomic and genetic characteri ...... for tyrosine kinase inhibitors

@nl

prefLabel

Genomic and genetic characteri ...... for tyrosine kinase inhibitors

@ast

Genomic and genetic characteri ...... for tyrosine kinase inhibitors

@en

Genomic and genetic characteri ...... for tyrosine kinase inhibitors

@nl

P1433

Q34104493-53B64A97-A27E-453C-986A-4E4882A0088C

P1476

Q34104493-C2E36193-7235-4822-8666-51FF6B1DE65D

P2093

Q34104493-1735E688-3A60-47A6-97D6-8FB54A0285F0

Q34104493-24B44F0C-2260-48CC-8E9A-2AF1739B426E

Q34104493-49F7687D-7178-496E-9A6A-60C5B8E3609C

Q34104493-9F6C09FB-EEBD-4BB2-A9FA-7F40FDD3D0CE

Q34104493-A0693428-CE5D-47A0-86CC-43247B69FE10

Q34104493-B0BB38BE-1B90-4E54-9FC8-F4DED8AEA28B

Q34104493-BC342784-7834-404F-AEA3-CAB0FEF6D911

Q34104493-D1D4595B-85AC-4E19-BF08-F0CFDFBF7A1C

Q34104493-FE9642D2-56A4-417E-8A15-8EFB8C4F6EDC

P2860

Q34104493-08584D87-944E-4270-BB90-1BCC7C88F5E3

Q34104493-0BB7D9F9-7BF2-4666-B3F0-C32325070E5E

Q34104493-10D239B9-E27F-4E1E-844F-62B1E3042168

Q34104493-148DA590-56E5-488C-B370-9DC640DDF888

Q34104493-1BEC174D-3AEA-4D0E-ABC3-C2C68BF8402F

Q34104493-2E6B3711-ECC9-48AC-9ADA-EC49B0CC8661

Q34104493-398B0B45-EED7-43B2-A4E2-B2F5F869DF0F

Q34104493-54B8C1B4-08AB-45E6-BFBE-8240158BD5E0

Q34104493-56C69C93-B0C2-4741-960D-05C43ECB0D1A

Q34104493-5A7CE7D0-FB2D-4242-9919-56C57F19A7B0

P304

Q34104493-AF28FBB0-BBAC-4C45-A851-DE9158B39165

P31

Q34104493-39C91040-E081-4C7E-8FCC-980EFBC5BD52

Q34104493-ffa78e30-2ae0-43bf-884e-c58a89f45605

P356

Q34104493-637455FC-58D2-41BF-9EA5-C8D56C27144E

P407

Q34104493-B67BC1BC-3415-4CFB-87E7-254BBE8E71B7

P433

Q34104493-71C03CD5-61E2-4479-8583-75BBBA9E35F8

P478

Q34104493-B185C259-7A61-4D6E-9A27-389469FBC55C

P50

Q34104493-099C7D39-572B-4A59-80AA-61BD98CA1884

Q34104493-679A3D68-061A-478E-9A46-77B553A5C394

Q34104493-B3B9B772-59A8-40F9-BA3A-D05F3BBE1AD3

P577

Q34104493-C2E0558F-E75F-40A3-9CDD-2DD112B18D11

P5875

Q34104493-F833FB77-8A8E-4822-957B-BA9CAF47297C

P698

Q34104493-999FB4BD-408C-4C10-8E07-8F44A26522D5

P921

Q34104493-8E7D3CBC-A1BB-43F8-94C3-2C1333577902

P932

Q34104493-CFEFA004-A19F-471C-ABDA-90F3505E752B

P356

J.GASTRO.2011.12.005

P1433

Gastroenterology

P1476

Genomic and genetic characteri ...... for tyrosine kinase inhibitors

@en

P2093

Andrew Barbour

http://www.w3.org/2001/XMLSchema#string

Bart Spee

http://www.w3.org/2001/XMLSchema#string

Boris R Blechacz

http://www.w3.org/2001/XMLSchema#string

Elizabeth A Conner

http://www.w3.org/2001/XMLSchema#string

Itzhak Avital

http://www.w3.org/2001/XMLSchema#string

Matthew C Gillen

http://www.w3.org/2001/XMLSchema#string

Mina Komuta

http://www.w3.org/2001/XMLSchema#string

Snorri S Thorgeirsson

http://www.w3.org/2001/XMLSchema#string

Valentina M Factor

http://www.w3.org/2001/XMLSchema#string

P2860

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

A gene-expression signature as a predictor of survival in breast cancer

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

PTK6 inhibits down-regulation of EGF receptor through phosphorylation of ARAP1

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes

Gene-expression profiles predict survival of patients with lung adenocarcinoma

Screening for epidermal growth factor receptor mutations in lung cancer

Stromal gene expression predicts clinical outcome in breast cancer.

Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.

P304

1021-1031.e15

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/J.GASTRO.2011.12.005

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

142

http://www.w3.org/2001/XMLSchema#string

P50

Lewis R. Roberts

Jesper B. Andersen

P577

2011-12-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51897164

http://www.w3.org/2001/XMLSchema#string

P698

22178589

http://www.w3.org/2001/XMLSchema#string

P921

cholangiocarcinoma

P932

3413201

http://www.w3.org/2001/XMLSchema#string